Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)

NCT00231413 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00231413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00231413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2005
Completion date
March 27, 2006
Enrollment
383 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus